We don't know why, but there are some gradients of infection.
I think we should put the same weight now on the co-factors as we have on HIV.
What perhaps should receive more attention is the effect of the treatment on the virus.
The idea of the live-virus vaccine is to produce in a continuous way some viral antigens.
Basic research is very useful, but it should be more geared toward application than it was before.
It's easier to learn things for life by the age of 12 and not the age of 18. This is just my guess.
It's clear that prevention will never be sufficient. That's why we need a vaccine that will be safe.
We are working with a biotech company, Calypte, which has designed a urine test for the HIV antibody.
I've participated in meetings where there were concerns by ethical experts. There is no clear solution.
Since most of the transmission is sexual transmission, you have a regional or local response to the virus.